Searched for
BIOSIMILAR ETANERCEPT
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Biocon Biologics launches product for autoimmune diseases in AustraliaBiocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating autoimmune di...
- Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countriesmAbxience, a majority-owned company of German drug maker Fresenius Kabi, also has partial ownership from Insud Pharma, will be responsible ...
- Biocon Biologics completes integration of Viatris' biosimilar business in 120 countriesThe company said over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integrat...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Biocon Biologics acquires Viatris' biosimilar business for $3.34 billionBBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...
- Irish drug regulator clears Lupin Pune unit after virtual inspectionLupin’s Pune facility is known for its R&D and manufacturing work related to biosimilars.
- Lupin aims to launch new products across geographies this fiscal"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market," company said.
- Lupin Pharma gets Good Manufacturing Certificate for its biologic plantBiosimilar Etanercept is used to fight a range of severe auto-immune disorders.
- Desi pharma companies top in biosimilars globallyBiosimilars are approved versions of biopharmaceuticals — complex medicines manufactured using live organisms, as against conventional drug...
- Biocon puts arthritis drug on backburnerBiocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel.
- Lupin-Mylan team up for biosimilar EtanerceptUnder the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with a...
- Lupin aims to be numero uno in biosimilar etanercept in JapanIt takes 12-13 months for the Japanese drug authorities to give product approvals.
- Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in JapanMumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...
- Lupin's JV completes global trials for RA biosimilarThe randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.
- Lupin forms Joint Venture with Japan's Yoshindo IncLupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.
- Lobby fears norms violation in Cipla's biosimilar drugA lobby group of biotech drug companies in India has raised concerns about the approval of Cipla's first biosimilar drug Etanercept.
- Cipla launches biosimilar for rheumatic disorders in IndiaDrug major Cipla said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in ...
Load More
